Use of remdesivir in patients with COVID-19: a systematic review and meta-analysis
ABSTRACT Objective: Studies in the literature regarding the use of remdesivir to treat COVID-19 patients have shown conflicting results. This study sought to answer questions related to the use of remdesivir for the treatment of patients hospitalized with moderate to severe COVID-19. Methods: This was a systematic review and meta-analysis including phase 3 randomized clinical trials (RCTs) and observational cohort studies selected from various databases, comparing patients hospitalized with moderate to severe COVID-19 receiving remdesivir and controls. Results: A total of 207 studies were retrieved, 9 of which met the eligibility criteria and were included in the study. The meta-analysis using RCTs alone showed no statistically significant differences regarding mortality or use of mechanical ventilation/extracorporeal membrane oxygenation between remdesivir and control groups, and the quality of evidence was moderate and low, respectively. The use of remdesivir increased the recovery rate by 6% (95% CI, 3-9); p = 0.004) and the clinical improvement rate by 7% (95% CI, 1-14); p = 0.02). Additionally, no significant differences in mortality were found between remdesivir and control groups when the meta-analysis used observational cohort studies alone (risk difference = −0.01 (95% CI, −0.02 to 0.01; p = 0.32), the quality of evidence being moderate, and the risk of adverse events was 4% ([95% CI, −0.08 to 0.01]; p = 0.09). Conclusions: The use of remdesivir for the treatment of patients with moderate to severe COVID-19 had no significant impact on clinically important outcomes.
Main Authors: | Tanni,Suzana E, Silvinato,Antonio, Floriano,Idevaldo, Bacha,Hélio A, Barbosa,Alexandre Naime, Bernardo,Wanderley M |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Pneumologia e Tisiologia
2022
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132022000101200 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of anticoagulants in patients with COVID-19: a living systematic review and meta-analysis
by: Batista,Diane R, et al.
Published: (2022) -
Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19
by: Barbosa,Alexandre Naime, et al.
Published: (2022) -
Antibiotics in the prophylaxis of COVID or in the treatment of mild COVID
by: Barbosa,Alexandre Naime, et al.
Published: (2022) -
The use of neutralizing monoclonal antibody in patients with COVID-19: a systematic review and meta-analysis
by: Tanni,Suzana Erico, et al.
Published: (2022) -
Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis
by: Tanni,Suzana E, et al.
Published: (2021)